Want to read (3)
De novo design of miniproteins targeting GPCRs
Muratspahić E, Feldman D, Kim DE, Qu X, Bratovianu AM, Rivera-Sánchez P, Voss JH, Hertz EPT, Jeppesen M, Dimitri F, Sakamoto K, Nallathambi A, Peceli P, Cao J, Cary BP, Belousoff MJ, Keov P, Trinh PNH, Chen Q, Ren Y, Fine J, Mishra S, Dalal A, Sinha S, Banerjee R, Ganguly M, Karuppusamy KV, Sappington I, Schlichthaerle T, Zhang JZ, Pillai A, Coventry B, Mihaljević L, Bauer M, Torres SV, Motmaen A, Lee GR, Tran L, Wang X, Goreshnik I, Vafeados DK, Svendsen JE, Hosseinzadeh P, Lindegaard N, Brandt M, Waltenspühl Y, Deibler K, Deweid L, Bennett A, Schöppe J, Dong T, Yan X, Oostdyk L, Cao W, Anantharaman L, Weisser JJ, Bastlund JF, Bundgaard C, Asuni AA, English JG, Stewart L, Halloran L, Spangler JB, Lieber A, Shukla AK, Sexton PM, Roth BL, Krumm BE, Wootten D, Tate CG, Norn C, Baker D.
2026
Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial
Melero I, Reis B, Rusterholz C, Epp A, Kratochwil NA, Wu C, Hettich M, Kazantzidis G, Rieder N, Schwalie PC, Badillo S, Kumpesa N, Thommen A, Vugts DJ, Moreno V, Lostes Bardaji J, Alvarez EC, de Andrea CE, Spanggaard I, Lee DH, Spicer J, Thistlethwaite F, Oh DY, Hollebecque A, Cirovic O, Symeonides SN
Nature cancer · 2026
An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments
Klatt MG, Aretz ZEH, Curcio M, Gejman RS, Jones HF, Scheinberg DA
Journal of proteomics · 2020